Grail, Inc. (NASDAQ:GRAL - Get Free Report) saw strong trading volume on Tuesday . 945,734 shares were traded during trading, a decline of 26% from the previous session's volume of 1,280,710 shares.The stock last traded at $61.89 and had previously closed at $55.02.
Analysts Set New Price Targets
Several research analysts recently weighed in on the company. Wolfe Research began coverage on Grail in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock. Morgan Stanley assumed coverage on shares of Grail in a research report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 price objective on the stock.
Check Out Our Latest Report on Grail
Grail Stock Performance
The firm has a 50 day moving average of $26.32 and a 200-day moving average of $19.06.
Grail (NASDAQ:GRAL - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The company had revenue of $38.25 million during the quarter, compared to the consensus estimate of $35.33 million. On average, equities analysts anticipate that Grail, Inc. will post -65.16 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. FNY Investment Advisers LLC bought a new position in shares of Grail in the fourth quarter valued at approximately $26,000. State of Tennessee Department of Treasury bought a new stake in Grail during the 4th quarter worth about $28,000. Lindbrook Capital LLC bought a new stake in Grail during the 4th quarter worth about $28,000. Sterling Capital Management LLC bought a new stake in Grail during the 4th quarter worth about $29,000. Finally, Wellington Shields Capital Management LLC bought a new stake in Grail during the 4th quarter worth about $33,000.
About Grail
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
